These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32926176)

  • 41. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug.
    Asero R
    Allergy; 2018 Nov; 73(11):2242-2244. PubMed ID: 29989179
    [No Abstract]   [Full Text] [Related]  

  • 42. Short courses of ciclosporin can induce long remissions in chronic spontaneous urticaria.
    Alves F; Calado R; Relvas M; Gomes T; Gonçalo M
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):e645-e646. PubMed ID: 35344624
    [No Abstract]   [Full Text] [Related]  

  • 43. Unique basophil microRNA signature in chronic spontaneous urticaria patients who respond to omalizumab.
    Al-Shaikhly T; MacDonald JW; Bammler TK; Altman MC; Ayars AG; Petroni DH; Tilles SA; Henderson WR
    Clin Exp Allergy; 2021 Dec; 51(12):1648-1652. PubMed ID: 34519110
    [No Abstract]   [Full Text] [Related]  

  • 44. [Clinical profile of patients with chronic urticaria in a tertiary care hospital of the social security system in Costa Ricas].
    Sedó-Mejía G; Lotz-Esquivel S; Monge-Ortega OP; Pino-García C
    Rev Alerg Mex; 2021; 68(4):225-232. PubMed ID: 34904558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ligelizumab for chronic spontaneous urticaria.
    Sabroe RA
    Br J Dermatol; 2020 Nov; 183(5):829-830. PubMed ID: 32002982
    [No Abstract]   [Full Text] [Related]  

  • 46. Scratch pleasurability is high in chronic spontaneous urticaria.
    Labib A; Yap QV; Smith P; Yosipovitch G
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3337-3338.e1. PubMed ID: 35973524
    [No Abstract]   [Full Text] [Related]  

  • 47. Omalizumab in severe chronic urticaria: are slow and non-responders different?
    Asero R
    Eur Ann Allergy Clin Immunol; 2021 Nov; 53(6):263-266. PubMed ID: 32914943
    [No Abstract]   [Full Text] [Related]  

  • 48. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis.
    Shaker M; Oppenheimer J; Wallace D; Lang DM; Rambasek T; Dykewicz M; Greenhawt M
    J Allergy Clin Immunol Pract; 2020; 8(7):2360-2369.e1. PubMed ID: 31751758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study.
    Asero R
    Eur Ann Allergy Clin Immunol; 2022 Jan; 54(1):30-33. PubMed ID: 33555151
    [No Abstract]   [Full Text] [Related]  

  • 51. Self-reported hair loss in patients with chronic spontaneous urticaria treated with omalizumab: an under-reported, transient side effect?
    Konstantinou GN; Chioti AG; Daniilidis M
    Eur Ann Allergy Clin Immunol; 2016 Sep; 48(5):205-7. PubMed ID: 27608479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of chronic spontaneous urticaria with the first exposure to general anaesthesia.
    Kim JC; Kim DC; Choi YW; Lee ES; Choi JW
    Clin Exp Allergy; 2022 Aug; 52(8):990-993. PubMed ID: 35587896
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria.
    Poddighe D; Vangelista L
    Cell Immunol; 2020 Dec; 358():104215. PubMed ID: 33137647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic inducible urticaria a particular form of chronic urticaria.
    Soria A
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):452-453. PubMed ID: 38391218
    [No Abstract]   [Full Text] [Related]  

  • 55. Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
    Ertaş R; Özyurt K; Yıldız S; Ulaş Y; Turasan A; Avcı A
    Iran J Allergy Asthma Immunol; 2016 Feb; 15(1):82-6. PubMed ID: 26996116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial.
    Sussman G; Hébert J; Gulliver W; Lynde C; Yang WH; Papp K; Gooderham M; Chambenoit O; Khalil S; DeTakacsy F; Vieira A; Rihakova L
    J Allergy Clin Immunol Pract; 2020; 8(7):2372-2378.e5. PubMed ID: 32272284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. "Omalizumab plus": Combining omalizumab with immunosuppression for treatment of refractory chronic urticaria: A multicenter UK series.
    Rutkowski K; Wagner A; Jui-Lin Choo K; Smith H; Savic S; Grattan CE
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1400-1401.e2. PubMed ID: 33181342
    [No Abstract]   [Full Text] [Related]  

  • 58. Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria.
    Muntyanu A; Ouchene L; Ben-Shoshan M; Netchiporouk E
    J Cutan Med Surg; 2020; 24(2):201-202. PubMed ID: 32208012
    [No Abstract]   [Full Text] [Related]  

  • 59. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
    Syrigos N; Grapsa D; Syrigou E
    Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):286-287. PubMed ID: 29249139
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines.
    Agache I; Rocha C; Pereira A; Song Y; Alonso-Coello P; Solà I; Beltran J; Posso M; Akdis CA; Akdis M; Brockow K; Chivato T; Del Giacco S; Eiwegger T; Eyerich K; Giménez-Arnau A; Gutermuth J; Guttman-Yassky E; Maurer M; Ogg G; Ong P; O'Mahony L; Schwarze J; Werfel T; Canelo-Aybar C; Palomares O; Jutel M
    Allergy; 2021 Jan; 76(1):59-70. PubMed ID: 32767573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.